Antibiotic Associated Diarrhoea (AAD)

AAD affects approx. 25% of people treated with antibiotics!¹

There is a risk that people who get stomach problems caused by their antibiotic treatment, discontinue their treatment prematurely. This can lead to reinfection or antibiotic-resistant bacteria. A Swedish study found that 20% of those treated with penicillin do not complete their treatment, because of problems such as diarrhoea.²

Why to prevent antibiotic associated diarrhoea (AAD) with BioGaia Protectis?

  • supports the protecting/necessary commensal bacteria

  • fights harmful bacteria without impairing the balance of the microflora

  • produces substances (Reuterin) that inhibit pathogenic microorganisms

  • can compete with pathogens for nutrients

  • can stimulate a nonspecific immune response to pathogens

Preventiv supplementation with probiotics has, according to several studies, been shown to reduce gut problems caused by antibiotics.

BioGaia Probiotic Drops and Tablets

Containing Limosilactobacillus reuteri Protectis, BioGaia Pobiotic Drops and Tablets promote the growth of good bacteria in the intestinal tract, re-establishing a healthy bacterial balance under antibiotic therapy.

BioGaia Dosage recommendations during antibiotic treatment:

1 chewable tablet or 5 drops daily, continue for 5 days following completion of antibiotic treatment.

Randomised, double-blind, placebo-controlled pilot study

Limosilactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhoea in hospitalised adults.

Cimperman L, Bayless G, Best K, Diligente A, (2011) J Clin Gastroenterol. 45:785-789. Intake of BioGaia ignificantly decreased incidence of antibiotic-associated diarrhoea (AAD) in hospitalised adults.



incidence of diarrhoea in patients receiving antibiotics + L. reuteri (BioGaia) vs 50% in the placebo group, (p=0.02).


  • Occurrence of diarrhoea was statistically less frequent in the L. reuteri (BioGaia) group.

  • Side-effects to the antibiotic treatment were fewer in the L. reuteri (BioGaia) group.

  • BioGaia ProTectis was well tolerated.


  • Prospective, randomized, placebo controlled study

  • 23 hospitalised patients treated with antibiotics

  • 13 received one tablet per day of L. reuteri (BioGaia) , and 10 received identical placebo for a total of 4 weeks.

Randomised placebo controlled trial

Limosilactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children.

Cimperman L, Bayless G, Best K, Diligente A, (2011) J Clin Gastroenterol. 45:785-789.


Significantly reduced frequency of abdominal distension, pain and defecation disturbances such as diarrhoea and constipation.


L. reuteri (BioGaia) supplementation during and after H. pylori eradication therapy significantly reduced the frequency and intensity of antibiotic-associated side-effects


  • Double blind, placebo-controlled study

  • 40 children aged 3-18 years diagnosed with H. pylori infection , received once daily

  • L. reuteri (BioGaia)(n=20) or placebo (n=20), as a supplement to the 10-day antibiotics eradication

  • therapy and for another 10 days post treatment.

We use cookies to make your experience of our website better.
Using this website means you are OK with this. Find out more.